Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Satellos Bioscience Inc Com V.ICO


Primary Symbol: ICOTF

iCo Therapeutics Inc is a Canada based biotechnology company. It is involved in the Research and development of ophthalmic indications. The company identifies, develops, and commercialize drug candidates with clinical history, and re-doses, reformulates and develops these drug candidates to treat sight and life-threatening diseases. Its in-licensed assets are iCo-008 and the Oral AmpB Delivery System. iCo-008 is a human monoclonal antibody targeting eotaxin-1 that acts as a messenger between...


GREY:ICOTF - Post by User

Post by shareswapperon Dec 10, 2020 12:14am
121 Views
Post# 32074464

The Holy Grail!!!

The Holy Grail!!!Looks like we could be starting a Phase II Trial in Vulvovaginal Candidiasis or a Phase II in Leishmaniasis!!!!  Sweet Jesus, this Oral Amp B has BLOCKBUSTER potential.

Not to mention, the Phase III for Bertilimumab in Bullous Pemphigoid with Alexion.  I heard that Alexion has developed a new sub cutaneous formulation!

Both of these Drugs are BILLION $$$$$ Drugs, why are we trading down here???? WHY?

Someone is gonna take us out here .....

https://www.newsfilecorp.com/release/66469/iCo-Therapeutics-Inc.-Announces-That-Oral-Amphotericin-B-iCo019-Results-Will-Be-Highlighted-During-the-American-Association-of-Pharmaceutical-Scientists-AAPS-Virtual-Meeting-October-26-November-3rd-2020
<< Previous
Bullboard Posts
Next >>